Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of SC Tocilizumab in pJIA and sJIA
NCT02165345Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2014
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 12
01
Overview
Phase 1, open-label, single-arm trial of tocilizumab in juvenile idiopathic arthritis (JIA) and Systemic Juvenile Idiopathic Arthritis (sJIA), sponsored by Roche. Primary endpoints: Juvenile Arthritis Disease Activity Score (JADAS-71) at 3 years and Percentage of Participants With Adverse Events at 5 years. Started Jul 2014; status: completed.
02
Drugs
tocilizumab
03
Conditions
juvenile idiopathic arthritis (JIA)Systemic Juvenile Idiopathic Arthritis (sJIA)
Beyond the preview
Go deeper on NCT02165345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165345.